Browse News
Filter News
Found 81 articles
-
Study of Kintor's c-Myc Degrader Published in Subsidiary Journal of Nature
3/14/2024
Kintor Pharmaceutical Limited announces that Kintor and its cooperative partner had published an article named MYC Induces CDK4/6 Inhibitors Resistance by Promoting pRB1 Degradation in a subsidiary journal of Nature—Nature Communications.
-
Kintor Pharma Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China
10/11/2023
Kintor Pharmaceutical Limited announced that its Hedgehog/SMO inhibitor GT1708F had obtained conditional approval to conduct Phase II clinical trial in China by the National Medical Products Administration for treatment of idiopathic pulmonary fibrosis.
-
Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
8/22/2023
Kintor Pharmaceutical Limited announced that the company has completed the enrollment of 180 patients for the Phase II clinical trial of its in-house developed first-in-class proteolysis targeting chimera compound GT20029 in China for the treatment of male androgenetic alopecia.
-
Kintor Pharma Announces Completion of First Patient Enrollment in Long-term Safety Phase III Trial of KX-826 for Treatment of AGA
7/19/2023
Kintor Pharmaceutical Limited announced that the company has initiated the long-term safety trial (the "Long-term Safety Trial") of KX-826, a potential first-in-class androgen receptor (AR) antagonist for the treatment of androgenetic alopecia (AGA) developed in-house, in China and has completed the first patient enrollment today.
-
Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
5/11/2023
Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the Phase II clinical trial of in-house developed KX-826 for the treatment of male androgenetic alopecia ("AGA") in the US has been completed successfully.
-
Kintor Pharma Announces 2022 Annual Results and Recent Business Progress
3/30/2023
Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced business highlights and financial results for the year ended 31 December 2022.
-
Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China
3/28/2023
Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939) announced that the company has completed the enrollment of 740 subjects recently for the Phase III clinical trial of its in-house developed first-in-class drug candidate KX-826 (pyrilutamide) in China for the treatment of male androgenetic alopecia (AGA) adults.
-
Kintor Pharma's KX-826 and GT20029 for Treatment of Androgenetic Alopecia (AGA) and Acne Presented at AAD 2023
3/21/2023
The 2023 Annual Meeting of American Academy of Dermatology Association was held from 17 to 21 March 2023 in New Orleans, Louisiana, United States.
-
Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World's First Topical Use PROTAC Compound
2/10/2023
Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced the positive top-line results from the U.S. Phase I clinical trial of GT20029, a Kintor Pharma in-house developed and fully owned proteolysis targeting chimera (PROTAC) compound.
-
Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met
12/1/2022
Kintor Pharmaceutical Limited announced results of phase II clinical trial of pyrilutamide, a potential first-in-class topical drug developed by the company, in China for the treatment of adult female androgeneticalopecia.
-
Kintor Pharma Announces Oral Presentation at ASH 2022 Highlighting the Data from Novel Dual c-Myc/GSPT1 Degrader GT19715
11/9/2022
Kintor Pharmaceutical Limited ("KintorPharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the results from the novel dual c-Myc/GSPT1 degrader GT19715 have been selected for oral presentation at the annual meeting of the American Society of Hematology 2022 (ASH 2022), and the abstract is available on ASH's official website.
-
Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US
10/27/2022
Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939) today announced that the company has completed the enrollment and dosing of 120 subjects for its U.S. phase I clinical trial of GT20029 for the treatment of androgenetic alopecia (AGA) and acne on 25 October 2022.
-
Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Acne Vulgaris in China
10/16/2022
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the enrollment of 160 patients for its phase II clinical trial of KX-826 in China for the treatment of acne vulgaris on 14 October 2022.
-
Kintor Pharma Announces Publication of Phase Ib Data from Pruxelutamide for AR+ mBC in EJC
9/29/2022
Kintor Pharmaceutical Limited announced that the results from a phase Ib study of pruxelutamide for the treatment of patients with androgen receptor positive metastatic breast cancer in China have been published in the international journal, European Journal of Cancer on September 28, 2022, further demonstrating the efficacy and safety of pruxelutamide in patients with AR+ mBC.
-
Kintor Announces 2022 Interim Results and Recent Business Update
8/29/2022
Kintor Pharmaceutical Limited today announced its 2022 interim results and released an update on its recent business highlights.
-
Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China
8/9/2022
Kintor Pharmaceutical Limited announced that the company has completed the enrollment and dosing of 92 subjects for its phase I clinical trial of GT20029 in China for the treatment of androgenetic alopecia and acne on August 8, 2022.
-
Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
8/3/2022
Kintor Pharmaceutical Limited today announced that the company completed the enrollment of 121 patients for its phase II clinical trial of KX-826 ("pyrilutamide").
-
Kintor Scientists Published Results of Study Showing Pruxelutamide's Inhibitory Effects on Acute Lung Injury and Its Molecular Mechanism of Anti-Inflammatory Response
7/18/2022
Recently, Kintor Pharma scientists published results of a study titled " Inhibitory Effects of GT0918 on Acute Lung Injury and the Molecular Mechanisms of Anti-inflammatory Response " in the preprint journal bioRxiv.
-
Kintor Pharma and Etana's Collaboration on Pruxelutamide's COVID-19 Project Awarded with Belt and Road Innovation Project and Fund Support from the Science and Technology Department of Jiangsu Province
6/14/2022
Kintor Pharmaceutical Limited announced that its "clinical trial cooperative research and development and overseas application demonstration of the anti-COVID-19 drug " project was selected as one of the Belt and Road Innovation Cooperation Projects and was included in the list of proposed projects for special fund supported by the Jiangsu Provincial Department of Science and Technology.
-
Kintor Pharma Included in MSCI China Index
5/15/2022
Kintor Pharmaceutical Limited announced that the company's stock has been included in the MSCI China Index, effective May 31, 2022.